Assessment of Physician Prescribing of Muscle Relaxants in the United States, 2005-2016

Authors:

Abstract
In response to the opioid epidemic, clinicians and patients are increasingly seeking alternatives to opioids for the management of musculoskeletal conditions. Centrally acting skeletal muscle relaxants (SMRs), such as baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine, and tizanidine, are labeled for acute musculoskeletal conditions including spasms and lower back pain; they are used off-label for neuropathic pain, chronic noncancer pain, temporomandibular disorder pain, and numerous nonpain conditions.1 A 2003 systematic review concluded that SMRs are effective for acute low back pain (although their comparative effectiveness vs analgesics or nonsteroidal anti-inflammatory drugs for acute low back pain is unknown), the evidence for chronic low back pain is less convincing, and SMRs must be used with caution because of central nervous system adverse effects, such as drowsiness and dizziness.2 Because of the lack of evidence regarding the long-term efficacy and safety of SMRs and the unquantified risk of abuse, dependence, and overdose,1,3 recommendations generally limit the use of SMRs to a maximum duration of 2 to 3 weeks.4 Despite such recommendations, a 1988-1994 study found that 44.5% of people taking SMRs were continuously treated for longer than 1 year.5 Carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol, metaxalone, and orphenadrine are all considered potentially inappropriate medications in older adults,6,7 in whom these agents are associated with sedation, cognitive impairment, and fracture.8 An additional concern regarding the inappropriate use of SMRs is the potential for drug-drug interactions, particularly with opioids.9

This publication has 16 references indexed in Scilit: